Rapport Therapeutics (RAPP) opened Q1 2026 with revenue of US$20 million, a basic EPS loss of US$0.42, and a net income loss of US$19.86 million, providing a clear snapshot of a company still in investment mode. Over the past year, the company has seen quarterly revenue move from US$0 to US$20 million, while quarterly basic EPS loss shifted between US$0.57 and US$0.75 before landing at US$0.42 in the latest quarter. This gives investors a clearer view of how top-line and per-share losses are evolving together. Overall, Q1 2026 shows early revenue beginning to come through while losses remain significant, keeping margins firmly in the red.

See our full analysis for Rapport Therapeutics.

With the headline numbers on the table, the next step is to see how this revenue ramp and ongoing losses line up against the prevailing narratives about Rapport Therapeutics and what investors expect from the stock.

Trailing US$107.3m loss keeps profitability distant

• On a trailing twelve month basis to Q1 2026, Rapport booked a net income loss of US$107.3 million and a basic EPS loss of US$2.56, showing that the recent US$19.9 million quarterly loss sits within a much larger ongoing burn.
• Bears point to these sustained losses as backing their view that the stock is high risk, and the figures here support several of those concerns:
  • The trailing loss of US$107.3 million compares with single quarter losses in the US$19.9 million to US$33.8 million range over the last year, so profitability is not close based on the reported numbers.
  • Analysis highlighting forecast average earnings declines of 15.4% a year for the next three years sits alongside this loss profile and fits a bearish stance that near term earnings progress is unlikely.

Stay grounded in the numbers before you lean into the more cautious arguments about this stock's future, and see how the detailed bear case lines up with these reported losses 🐻 Rapport Therapeutics Bear Case.

US$20m revenue on a small base

• Q1 2026 is the first period in this data set to show revenue, at US$20 million, compared with US$0 in each of the prior five quarters, while trailing twelve month revenue now registers at US$20 million after being reported as effectively zero a year ago.
• Bullish commentary often focuses on projected revenue growth of about 56.7% a year, and the shift from effectively no reported revenue to US$20 million in the latest quarter ties directly into that argument:
  • The move from US$0 revenue across all of 2025 to US$20 million in Q1 2026 provides the first concrete top line contribution that bulls can point to, even though it sits against a large net loss.
  • Forecasts that emphasize rapid percentage growth are based on this very small starting point, so the current data supports the bullish focus on growth potential but also shows that the absolute revenue level is still modest next to the US$107.3 million trailing loss.

If you want to see how growth focused investors frame this first revenue step against the ongoing losses, check out the more optimistic take and how it uses these numbers 🐂 Rapport Therapeutics Bull Case.

P/B of 3.7x with recent dilution

• The stock trades on a P/B of 3.7x, which sits above the US Pharmaceuticals industry average of 2.7x and slightly above the peer average of 3.6x, while shareholders have also faced material dilution over the past year.
• Critics highlight this mix of a higher than average P/B ratio, continued losses and dilution as a key part of their cautious view, and the figures give that view some clear anchors:
  • With trailing twelve month revenue of US$20 million and a net loss of US$107.3 million, paying a premium to the sector on P/B means the current price of US$39.93 is being supported mainly by expectations rather than current profitability.
  • The reference to substantial shareholder dilution in the last year means existing holders now own a smaller share of a business that still reports zero profitable quarters in this dataset, which fits squarely with a bearish concern about financing risk.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Rapport Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With both risks and rewards on the table, does the balance of sentiment fit how you see Rapport Therapeutics right now, or not quite? Act quickly, review the figures for yourself, and weigh up the 1 key reward and 4 important warning signs 1 key reward and 4 important warning signs.

See What Else Is Out There

Rapport Therapeutics combines a trailing US$107.3 million loss, significant dilution, and no profitable quarters, so risk remains high relative to its small revenue base.

If that level of uncertainty feels uncomfortable, you can shift your focus toward companies screened for resilience and financial stability by checking out the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.